Join our #WomeninRCC webinar on July 17! Grateful to Lynn Schuchter for her time & wisdom. Will also have 3 early career women recap their #ASCO24 presentations.
Thanks Kidney Cancer for organizing!

Register here:
bit.ly/3VofzVm

Congratulations Felix Feng!! Well deserved.

Conversations sparked. Connections made. More than 45,000 attendees came together at #ASCO24 to explore the art & science of oncology and left inspired to change the future of cancer care. Thanks to all who joined us!

Save the date for #ASCO25 : May 30–June 3, 2025

Patients & physicians together — Laura Esfeller Katie Coleman Dena Battle — you are the real heroes advocating for patients here w/ us & those who have left our 🌍. We do what we do because of you.
Awesome we now have survivors in #kidneycancer to lend 1st hand advocacy. 💖

Was fortunate to be a small part of #ASCO24 with ⭐️ Jarushka Naidoo Tian Zhang, MD, MHS Melina Marmarelis Charu Aggarwal, MD, MPH, FASCO Patrick Forde Lecia Sequist, MD, MPH and many others including @asco leadership. Looking forward to next year under Dr. Zon ASCOPres and Erika Hamilton, MD!

Congrats Arthi Sridhar!
UTSW Simmons Cancer Center UTSW Hematology & Oncology #ASCO24

Always eloquent from the man/the legend Toni Choueiri, MD — #kidneycancer biomarkers from #CLEAR ASCO #ASCO24

Dear Colleagues at #ASCO24
An honor to introduce our OncoAlert 🚨faculty and Heart and Soul of the Network Toni Choueiri, MD 🇺🇸of Dana-Farber who discusses Biomarker Analysis of CLEAR trial in #KidneyCancer

Sumanta K. Pal, MD, FASCO Cristiane D Bergerot Daniel Heng Andrea Apolo, M.D. Toni Choueiri, MD Petros Grivas

Fantastic presentation by Dr. Shilpa Gupta 👉pts reported outcomes from ph3 EV-302 trial ASCO #ASCO24 👉Rx with enfortumab+pembro significantly improved OS without adversely affecting QOL, pain or functioning. Tom Powles Bladder Cancer Advocacy Network OncoAlert Umang Swami

40% response rate for chemo +pembro in advanced penile cancer #ASCO24 HPV16-positive (cORR 55.6%) and TMB-high (cORR 75%) potentially enrich. Great investigator initiated study from LACOG and Fernando Maluf


Better results with ipi/nivo in biomarker selected population of #prostatecancer . 40% response but also 40% grade 3+ diarrhea with higher dose ipi. Zang et al reported 50% response with pembro in hi TMB (JAMA Onc 2024). ICI clearly benefits select pts w/mCRPC

Excited to see you take on the scientific planning committee leadership for next year’s meeting, Erika Hamilton, MD!!

Wonderful session — great job Jessica Hawley MD MS Alex Chehrazi-Raffle, MD!

Masterful presentation by Shilpa Gupta discussing patient-reported outcomes phase III trial of EV+P vs. PBC in untreated la/mUC:

Patients in the EV+P group have improved survival compared with PBC without detriment to GHS/QoL, pain, or functioning!

Tom Powles Cleveland Clinic